iRadimed Corporation (NASDAQ:IRMD) Plans $0.50 Special Dividend

iRadimed Corporation (NASDAQ:IRMD) announced a special dividend on Monday, December 8th. Stockholders of record on Wednesday, December 17th will be given a dividend of 0.50 per share by the medical equipment provider on Tuesday, December 30th. The ex-dividend date is Wednesday, December 17th.

iRadimed has a dividend payout ratio of 34.2% meaning its dividend is sufficiently covered by earnings. Analysts expect iRadimed to earn $2.00 per share next year, which means the company should continue to be able to cover its $0.68 annual dividend with an expected future payout ratio of 34.0%.

iRadimed Price Performance

Shares of IRMD stock traded up $0.91 during trading on Monday, hitting $95.48. 71,897 shares of the stock traded hands, compared to its average volume of 50,765. The firm has a market capitalization of $1.21 billion, a P/E ratio of 57.87 and a beta of 1.06. iRadimed has a 52-week low of $47.48 and a 52-week high of $98.24. The firm’s fifty day moving average price is $81.57 and its 200-day moving average price is $70.16.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The company had revenue of $21.20 million for the quarter, compared to analyst estimates of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, equities research analysts expect that iRadimed will post 1.66 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on IRMD shares. Lake Street Capital reissued a “buy” rating and set a $100.00 price objective on shares of iRadimed in a report on Monday, November 3rd. Wall Street Zen lowered shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Roth Capital set a $90.00 price objective on iRadimed in a report on Friday, October 31st. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a report on Thursday. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, iRadimed currently has an average rating of “Moderate Buy” and an average price target of $87.33.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.